SUPPLY AGREEMENTSupply Agreement • November 7th, 2024 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledNovember 7th, 2024 Company Industry JurisdictionThis Supply Agreement (the “Supply Agreement”) is entered into as of September 3, 2024 (the “Effective Date”) by and between Rigel Pharmaceuticals, Inc., a Delaware company having an address at 611 Gateway Blvd., Suite 900, South San Francisco, CA 94080, USA (“Rigel”) and Kissei Pharmaceutical Co. Ltd., a Japanese company having an address at 19-48 Yoshino, Matsumoto, Nagano 399-8710, Japan (“Kissei”). Rigel and Kissei may be referred to herein individually as a “Party” or collectively as the “Parties”.
4th Amendment to the COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • November 7th, 2024 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations
Contract Type FiledNovember 7th, 2024 Company IndustryThis 4th Amendment to the COLLABORATION AND LICENSE AGREEMENT (the “Amendment”) is made and entered into as of September 3, 2024, by and between RIGEL PHARMACEUTICALS, INC., a Delaware company having an address at 611 Gateway Blvd., Suite 900, South San Francisco, CA 94080, USA (“Rigel”) and KISSEI PHARMACEUTICAL CO. LTD., a Japanese company having an address at 19-48 Yoshino, Matsumoto, Nagano 399-8710, Japan (“Kissei”). Rigel and Kissei may be referred to herein individually as a “Party” or collectively as the “Parties”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Collaboration and License Agreement • November 7th, 2024 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledNovember 7th, 2024 Company Industry JurisdictionThis Collaboration and License Agreement (this “Agreement”) is entered into as of September 3, 2024 (the “Effective Date”), by and between Rigel Pharmaceuticals, Inc., a Delaware company having an address at 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080, USA (“Rigel”) and Kissei Pharmaceutical Co. Ltd., a Japanese company having an address at 19-48 Yoshino, Matsumoto, Nagano 399-8710, Japan (“Kissei”). Rigel and Kissei may be referred to herein individually as a “Party” or collectively as the “Parties”.